Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Immunogenicity of COVID-19 vaccination in transplant and CAR-T therapy recipients

Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Westwood, KS, gives an overview of the findings of a study investigating the immunogenicity of COVID-19 vaccination in hematopoietic stem cell transplant (HSCT) and CAR-T therapy recipients. The study found that patients who had received CAR-T therapy or HSCT had lower antibody levels compared to the general population. In addition, the time interval between transplantation or CAR-T therapy and vaccine administration, as well as presence of graft-versus-host disease (GvHD), and immunosuppressive therapy were all found to significantly impact vaccine immunogenicity. Overall, the recommendation remains to vaccinate HSCT and CAR-T recipients at three months and administer the booster vaccine after one year. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.